ENDOMETRIAL STEM CELLS AND METHODS OF MAKING AND USING SAME

• US 20090053182A1
• Filed: 05/27/2008
• Published: 02/26/2009
• Est. Priority Date: 05/25/2007
• Status: Abandoned Application

• Current Assignee: Medistem Laboratories, Inc.
• Original Assignee: Medistem Laboratories, Inc.
• Inventors: Meng, Xiaolong, ICHIM, THOMAS E., Riordan, Neil H.
• Application Number:
  US12/127,697
• Publication Number:
  US 20090053182A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 35/545 Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
• CPC Class Codes: A61K 38/1858 Platelet-derived growth factor [PDGF]
• CPC Class Codes: A61K 38/1891 Angiogenesic factors; Angiogenin
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: A61K 38/4886 Metalloendopeptidases (3.4.24), e.g. collagenase
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C12N 5/0602 Vertebrate cells
• CPC Class Codes: C12N 5/0607 Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696
• CPC Class Codes: C12N 5/0634 Cells from the blood or the immune system
• CPC Class Codes: C12N 5/0681 Cells of the genital tract; Non-germinal cells from gonads
• CPC Class Codes: C12N 5/0682 Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells oocytes C12N5/0609
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention provides pluripotent stem cells and methods for making and using pluripotent stem cells. Pluripotent stem cells, among other things, can differentiate into various cell lineages in vitro, ex vivo and in vivo. Pluripotent stem cells, among other things, can also be used to produce conditioned medium.

Claims

1. A human pluripotent stem cell that expresses a marker selected from CD29, CD41a, CD44, CD90, and CD105, and having an ability to proliferate at a rate of 0.5-1.5 doublings per 24 hours in a growth medium.

2. The human pluripotent stem cell of claim 1, wherein said cell further expresses a marker selected from NeuN, CD9, CD62, CD59, Actin, GFAP, NSE, Nestin, CD73, SSEA-4, hTERT, Oct-4, and tubulin.

3. The human pluripotent stem cell of claim 1, wherein said cell further expresses a marker selected from hTERT and Oct-4, but does not express a STRO-1 marker, and has an ability to undergo cell division in less than 24 hours in a growth medium.

4. The human pluripotent stem cell of claim 1, wherein said cell further expresses a STRO-1 marker, and has an ability to proliferate at a rate of 0.5-0.9 doublings per 24 hours in a growth medium.

6. The human pluripotent stem cell of claim 1, wherein said cell produces matrix metalloprotease 3 (MMP3), matrix metalloprotease 10 (MMP10), GM-CSF, PDGF-BB or angiogenic factor ANG-2.

7. The human pluripotent stem cell of claim 1, wherein said cell is derived or originates from endometrium, endometrial stroma, endometrial membrane, or menstrual blood.

19. The human pluripotent stem cell of claim 1, wherein said cell is capable of differentiating into an adipogenic, endothelial, hepatic, osteogenic, neural, pancreatic or myocytic cell lineage.

20. The human pluripotent stem cell of claim 1, wherein said cell has a stable karyotype for at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more cell divisions.

24. The cell population of claim 1, wherein said cell is capable of stimulating, inducing, increasing, promoting, enhancing or augmenting a reparative process in a host.

25. The human pluripotent stem cell of claim 1, wherein said cell is capable of suppressing, inhibiting, reducing, decreasing, preventing, blocking, limiting or controlling a T cell mediated response in vitro or in vivo.

28. The human pluripotent stem cell of claim 1, wherein said mesenchymal cell marker is one or more of:

CD54, CD106, an HLA-I marker, vimentin, ASMA, collagen-1, or fibronectin, but not a HLA-DR, CD1 17, or a hemopoietic cell marker.

43. The human pluripotent stem cell of claim 1 wherein said cell or cells is capable of stimulating angiogenesis, inhibiting fibrosis or scar tissue formation, inhibiting inflammation, inhibiting undesired or pathological apoptosis.

44. The human pluripotent stem cell of claim 1 wherein said cell or cells is capable of stimulating endogenous progenitor cell proliferation, stimulation of endogenous stem cell proliferation, stimulation of endogenous progenitor cell differentiation, stimulation of endogenous stem cell differentiation, stimulation of exogenous progenitor cell proliferation, stimulation of exogenous stem cell proliferation, stimulation of exogenous progenitor cell differentiation, stimulation of exogenous stem cell differentiation.

57. A medium incubated with the cell population of claim 1 for a period of about 1-72 hours, 3-7 days, or more.

58. The medium of claim 57, wherein the medium comprises a matrix metalloprotease 3 (MMP3), matrix metalloprotease 10 (MMP10), GM-CSF, PDGF-BB or angiogenic factor ANG-2.

59. The medium of claim 57, wherein said medium stimulates, increases, induces, enhances or augments cell survival, viability, growth, proliferation or differentiation of a totipotent stem cell, a pluripotent stem cell, a multipotent stem cell or a differentiated cell.

61. A method of producing a conditioned growth medium comprising, contacting a liquid growth medium with the cell population of claim 1 under conditions suitable for viability of said population of cells for a period of about 1-72 hours, 3-7 days or more.

65. A method of stimulating hematopoiesis comprising administering to a subject the conditioned growth medium of claim 57 in an amount sufficient to stimulate hematopoiesis.

66. A method of inhibiting inflammation comprising administering to a subject the conditioned growth medium of claim 57 in an amount sufficient to inhibit inflammation.

67. A method of treating a subject in need of stimulation of angiogenesis, comprising administering the cell population of claim 1 to the subject in an amount sufficient to treat the subject.

77. A method of treating a subject in need of osteocytes or an osteocyte function comprising administering the cell population of claim 1 to the subject in an amount sufficient to increase osteocyte numbers, stimulate osteocyte formation or increase or stimulate an osteocyte function.

81. A method of treating a subject having or at risk of having a neurological or muscular disease or disorder, comprising administering the cell population of claim 1 to the subject in an amount sufficient to treat the neurological or muscular disease or disorder.

113. A method of increasing numbers of T regulatory cells in a subject, comprising administering human pluripotent stem cell of claim 1, or the population or plurality of cells of claim 1, to a subject under conditions facilitating increased numbers of T regulatory cells, thereby increasing numbers of T regulatory cells in the subject.

128. A method of stimulating, increasing, inducing, augmenting, or enhancing immunological tolerance or treating an autoimmune disorder comprising administering the cell population of claim 1 to the subject in an amount sufficient to stimulate, increase, induce, augment, or enhance immunological tolerance or treat the autoimmune disorder.

130. A method of stimulating, increasing, inducing, augmenting, or enhancing hematopoiesis comprising administering the cell population of claim 1 to the subject in an amount sufficient to stimulate, increase, induce, augment or enhance hematopoiesis.

131. A method of stimulating, increasing, inducing, augmenting, or enhancing Angiogenesis comprising administering the cell population of claim 1 to the subject in an amount sufficient to stimulate, increase, induce, augment or enhance angiogenesis.

5. (canceled)

8-18. -18. (canceled)

21-23. -23. (canceled)

26-27. -27. (canceled)

29-42. -42. (canceled)

45-56. -56. (canceled)

60. (canceled)

62-64. -64. (canceled)

68-76. -76. (canceled)

78-80. -80. (canceled)

82-112. -112. (canceled)

114-127. -127. (canceled)

129. (canceled)